In a deal valued at 25 billion dollars, the Irish Actavis has purchased Forest for $89.49 a share, 35% over Friday;s value.  The combination is designed to fit with new health care law in the US.   The combined company with offer a wide range of generic and brand name drugs to large consortiums of doctors and insurers.  Carl Icahn, activist shareholder supreme, holds 11.4 % of Forest’s shares.  Mr. Icahn called Tuesday’s deal a huge win for shareholders and “yet another validation of the activist investment philosophy,”